Science
Johnson and Johnson Reports Breakthrough Early Results for Prostate Cancer Antibody Therapy
Median survival for those with advanced mCRPC varies widely from 13.5 to 31.6 months depending on prior treatment history and disease burden
Subscriber access
Full story for subscribers
Sign in with your subscribed Google account to read the full article.
Checking your access…
